ENLIVEX LTD (ENLV) Stock Price & Overview
NASDAQ:ENLV • IL0011319527
Current stock price
The current stock price of ENLV is 1.02 USD. Today ENLV is down by -5.56%. In the past month the price increased by 0.99%. In the past year, price decreased by -2.39%.
ENLV Key Statistics
- Market Cap
- 242.128M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.55
- Dividend Yield
- N/A
ENLV Stock Performance
ENLV Stock Chart
ENLV Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ENLV. When comparing the yearly performance of all stocks, ENLV is one of the better performing stocks in the market, outperforming 75.36% of all stocks.
ENLV Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ENLV. No worries on liquidiy or solvency for ENLV as it has an excellent financial health rating, but there are worries on the profitability.
ENLV Earnings
ENLV Forecast & Estimates
8 analysts have analysed ENLV and the average price target is 13.26 USD. This implies a price increase of 1200% is expected in the next year compared to the current price of 1.02.
ENLV Groups
Sector & Classification
ENLV Financial Highlights
Over the last trailing twelve months ENLV reported a non-GAAP Earnings per Share(EPS) of -0.55. The EPS increased by 43.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -60.66% | ||
| ROE | -72.66% | ||
| Debt/Equity | 0 |
ENLV Ownership
ENLV Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.82 | 364.65B | ||
| AMGN | AMGEN INC | 15.24 | 188.631B | ||
| GILD | GILEAD SCIENCES INC | 15.52 | 175.177B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.42 | 116.358B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.68 | 77.963B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.84 | 41.258B | ||
| INSM | INSMED INC | N/A | 31.039B | ||
| NTRA | NATERA INC | N/A | 28.733B | ||
| BIIB | BIOGEN INC | 11.29 | 26.917B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.55 | 23.098B | ||
| MRNA | MODERNA INC | N/A | 20.683B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 19.837B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.676B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ENLV
Company Profile
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Company Info
IPO: 2014-07-30
ENLIVEX LTD
14 Einstein St.
Ness Ziona 7403618 IL
CEO: Oren Hershkovitz
Employees: 36
Phone: 97286623301
ENLIVEX LTD / ENLV FAQ
What does ENLV do?
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
What is the current price of ENLV stock?
The current stock price of ENLV is 1.02 USD. The price decreased by -5.56% in the last trading session.
Does ENLIVEX LTD pay dividends?
ENLV does not pay a dividend.
What is the ChartMill rating of ENLIVEX LTD stock?
ENLV has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is ENLIVEX LTD (ENLV) stock traded?
ENLV stock is listed on the Nasdaq exchange.
Should I buy ENLV stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ENLV.